2022
Characterization of parental intention to vaccinate elementary school aged children in the state of California
Dudley M, Barnett E, Paulenich A, Omer S, Schuh H, Proveaux T, Buttenheim A, Klein N, Delamater P, McFadden S, Patel K, Salmon D. Characterization of parental intention to vaccinate elementary school aged children in the state of California. Vaccine 2022, 41: 630-635. PMID: 36543683, PMCID: PMC9762501, DOI: 10.1016/j.vaccine.2022.12.030.Peer-Reviewed Original ResearchConceptsCOVID-19 vaccinationCoronavirus disease 2019 (COVID-19) vaccinesCOVID-19 vaccine confidenceSchool-entry mandatesEmergency use authorizationCOVID-19 vaccineUS FDA approvalCOVID-19Vaccine uptakeChildhood vaccinesHesitant parentsVaccine confidenceFDA approvalSociodemographic characteristicsVaccineParental intentionChildrenVaccinationCalifornia parentsPublic healthSchool childrenParental attitudesApprovalParentsUptakeClinical Phenotypes of Immediate First-Dose Reactions to mRNA COVID-19: A Multicenter Latent Class Analysis
Stone CA, Robinson LB, Li L, Krantz MS, Kwah JH, Ortega G, Mancini C, Wolfson AR, Saff RR, Samarakoon U, Hong DI, Koo G, Chow TG, Gruchalla R, Liao JX, Kuster JK, Price C, Ahola C, Khan DA, Phillips EJ, Banerji A, Blumenthal KG. Clinical Phenotypes of Immediate First-Dose Reactions to mRNA COVID-19: A Multicenter Latent Class Analysis. The Journal Of Allergy And Clinical Immunology In Practice 2022, 11: 458-465.e1. PMID: 36108922, PMCID: PMC9468049, DOI: 10.1016/j.jaip.2022.08.048.Peer-Reviewed Original ResearchConceptsMRNA COVID-19 vaccineNovel clinical phenotypesCOVID-19 vaccineDose 1Second doseClinical phenotypeObjective signsLatent class analysisMRNA coronavirus disease 2019 (COVID-19) vaccinesDose toleranceAllergy/immunology specialistsMRNA COVID-19 vaccinationCoronavirus disease 2019 (COVID-19) vaccinesSelf-limiting symptomsFirst-dose reactionsU.S. academic medical centersLog-binomial regressionCOVID-19 vaccinationDistinct clinical phenotypesAcademic medical centerImmediate reactionsImmunology specialistsClass analysisAllergic symptomsRetrospective studyIpsilateral Malignant Axillary Lymphadenopathy and Contralateral Reactive Lymph Nodes in a COVID-19 Vaccine Recipient With Breast Cancer
Adin ME, Wu J, Isufi E, Tsui E, Pucar D. Ipsilateral Malignant Axillary Lymphadenopathy and Contralateral Reactive Lymph Nodes in a COVID-19 Vaccine Recipient With Breast Cancer. Journal Of Breast Cancer 2022, 25: 140-144. PMID: 35380021, PMCID: PMC9065355, DOI: 10.4048/jbc.2022.25.e12.Peer-Reviewed Case Reports and Technical NotesLymph nodesNodal enlargementAxillary lymphadenopathyMRNA coronavirus disease 2019 (COVID-19) vaccinesBilateral axillary lymph nodesCOVID-19 vaccine recipientsRight-sided lymph nodesMRNA COVID-19 vaccinationCoronavirus disease 2019 (COVID-19) vaccinesIpsilateral axillary lymphadenopathyMalignant axillary lymphadenopathyAxillary lymph nodesPre-menopausal femalesRight breast lumpBreast cancer patientsCommon benign conditionReactive lymph nodesCOVID-19 vaccinationPotential disease progressionMagnetic resonance imagingVaccine recipientsSecond doseContralateral nodesCortical thickeningBreast lump
2020
Clinical Outcomes Of A COVID-19 Vaccine: Implementation Over Efficacy
Paltiel AD, Schwartz JL, Zheng A, Walensky RP. Clinical Outcomes Of A COVID-19 Vaccine: Implementation Over Efficacy. Health Affairs 2020, 40: 42-52. PMID: 33211536, PMCID: PMC7931245, DOI: 10.1377/hlthaff.2020.02054.Peer-Reviewed Original ResearchConceptsCOVID-19 vaccineVaccine efficacyCoronavirus disease 2019 (COVID-19) vaccinesSignificant vaccine hesitancyClinical outcomesClinical trialsVaccination programVaccine hesitancyEpidemic severityVaccineAuthorized vaccinesHealth officialsCumulative infectionsEfficacyVaccine productionDistribution programSeverityOutcomesUrgent needHospitalizationVaccinationInfectionTrialsGlobal efforts
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply